Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.

Bioorganic & medicinal chemistry letters - 1 Oct 2009

Boloor Amogh, Hanway Denise, Joshi Maria, Winn David T, Mendez Gabriel, Walls Marlena, Wei Ping, Qian Fuxin, Zhang Xiaoli, Zhang Yuliang, Hepperle Michael E, Li Xinqiang, Campbell David A, Betancort Juan M

Abstract excerpt

A new series of NS3/4A protease boronic acid inhibitors is described. The compounds show good biochemical potency and cellular activity. The peptidomimetic inhibitors were evaluated against proteases from different HCV genotypes and clinically relevant NS3/4A mutants. Compound 28 displayed subnanomolar to single digit nanomolar potencies in the enzymatic assays and an EC50 of 25 nM in the replicon cell-based assay.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Boronic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Intracellular Signaling Peptides and Proteins

Share to Mutant Proteins

Share to Protease Inhibitors

Share to Viral Nonstructural Proteins

Share to Viral Proteins

Source

Identifiers

PMID: 19713109
DOI: 10.1016/j.bmcl.2009.08.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.PMID 19713109Read ↗

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.Semantic proximity Read ↗

Expanding the chemical space of anti-HCV NS5A inhibitors by stereochemical exchange and peptidomimetic approaches.Semantic proximity Read ↗

Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect.Semantic proximity Read ↗

MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.Semantic proximity Read ↗

Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.Semantic proximity Read ↗

Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.Semantic proximity Read ↗

Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.Semantic proximity Read ↗

Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B.Semantic proximity Read ↗

Isosorbide-based peptidomimetics as inhibitors of hepatitis C virus serine protease.Semantic proximity Read ↗

Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture.Semantic proximity Read ↗

MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.Semantic proximity Read ↗

NS5A--from obscurity to new target for HCV therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.